While the 340B program “has merit when used as intended,” it has “strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.
Bayer gave the statement to 340B Report late yesterday in response to a request to elaborate on its decision to impose conditions on 340B pricing when hospitals use contract pharmacies. Its statement arrived too late to be included in our Feb. 1 article about its new policy.
While the 340B program “has merit when used as intended,” it has strayed far from its original purpose, creating a profit stream that is enriching middlemen versus benefitting patients,” drug manufacturer Bayer told 340B Report yesterday.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
